Coherus Oncology, Inc. (CHRS): Net Income
$168.02M
Year ended 2025-12-31
-$132.13M
Trailing 12 months to 2026-06-30
+4.9%
5-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $168.02M | +489.4% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $28.51M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$237.89M | n/m | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | -$291.75M | n/m | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | -$287.10M | n/m | 2024-03-15, From 2021-01-01 |
| 2020-12-31 | $132.24M | +47.2% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $89.83M | n/m | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | -$209.34M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$238.17M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$127.34M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$223.26M | n/m | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | -$87.13M | n/m | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | -$53.63M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$33.02M | n/a | 2015-03-23, From 2012-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $168.02M | +489.4% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | -$74.15M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$119.72M | n/m |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | -$99.96M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | -$70.81M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$114.20M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$52.49M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$146.95M | n/m |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | -$174.32M | n/m |
Compare CHRS, TECX, VYGR, LXEO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗